Key result
Phase 1 cardiac rehabilitation combined with standard pharmacotherapy yielded no significant between-group differences in post-treatment NT-proBNP levels (1889.0 vs 1439.61 pg/ml, p=0.188) or hemodynamic parameters compared to standard therapy alone, despite significant within-group improvements.
Why the study?
The study was conducted to assess the impact of phase 1 cardiac rehabilitation on cardiac function and hemodynamic changes in patients with coronary heart disease and acute heart failure.
Does phase 1 cardiac rehabilitation combined with standard pharmacotherapy improve NT-proBNP and hemodynamic parameters in patients with coronary heart disease and acute heart failure?
RCT (n=98)
Computerized random number generator with block size of 2
No
Does phase 1 cardiac rehabilitation combined with standard pharmacotherapy improve NT-proBNP and hemodynamic parameters in patients with coronary heart disease and acute heart failure?
Phase 1 cardiac rehabilitation combined with standard pharmacotherapy improved within-group hemodynamic parameters but did not show statistically significant differences compared to standard pharmacotherapy alone.
Purpose: The purpose of the study was to access the impact of phase 1 cardiac rehabilitation (CR) on cardiac function and hemodynamic changes in patients with coronary heart disease (CHD) and acute heart failure (AHF). Materials and methods: A total of 98 patients with CHD and AHF were recruited and randomized into two groups. Control group received standard pharmacotherapy and CR group received standard pharmacotherapy combined phase 1 CR. NT-proBNP and hemodynamic parameters measured by impedance cardiography (ICG) were estimated at baseline and at the end of treatment period. Results: Phase 1 CR combined routine medical treatment could lower NT-proBNP levels. The percentage of high-risk patients was significantly decreased in CR group, although the post-treatment NT-proBNP level between control group and CR group showed no significant differences. Similarly, most hemodynamic parameters improved in the CR group, but not in the control group, suggesting that phase 1 CR in combination with the standard pharmacotherapy improved hemodynamic characteristics by elevating cardiac output, ameliorating preload, improving systolic and diastolic function, and relieving afterload, although the post-treatment hemodynamic parameters showed no statistically significant differences between the control group and the CR group. Conclusion: Phase 1 CR combined routine medication can improve cardiac function and hemodynamic characteristics in patients with CHD and AHF. Thus, recommendation of phase 1 CR to stable patients is necessary.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2022) conducted an RCT in Coronary heart disease and acute heart failure (n=98). Phase 1 cardiac rehabilitation vs. Standard pharmacotherapy alone was evaluated on Post-treatment NT-proBNP level (pg/ml) (p=0.188). Phase 1 cardiac rehabilitation combined with standard pharmacotherapy yielded no significant between-group differences in post-treatment NT-proBNP levels (1889.0 vs 1439.61 pg/ml, p=0.188) or hemodynamic parameters compared to standard therapy alone, despite significant within-group improvements.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: